Profile picture for user iuliane
Iulian Ernst
Senior Editor

Iulian studied physics at the University of Bucharest, and he sees himself as a physicist in the broadest sense of the word. He also studied economics at Charles University in Prague and Central European University in Budapest, after a master’s program in business administration at Bucharest Academy of Economic Studies. Since recently, he’s been exploring coding and data analysis for business and economics. As a freelancer, he worked for nearly two decades as an analyst for ISI Emerging Markets, Euromonitor International, Business New Europe, but also as a consultant for OMV Petrom and UkrAgroConsult. Iulian was part of the founding team of Ziarul Financiar. At Romania Insider, which he joined in 2018, he is reviewing the latest economic developments for the premium bulletins and newsletters. He would gladly discuss topics such as macroeconomics, emerging markets, Prague, energy sector including renewable, Led Zeppelin, financial services, as well as tech start-ups and innovative technologies. Email him at iulian@romania-insider.com. 

 

Study: Pharma sales to grow by 5% this year driven by inflation, relaxation

The aggregated but not consolidated sales of producers, distribution firms and retailers in the pharmaceutical industry will rise by some 5% to RON 70 bln (EUR 14 bln) after the 2.6% advance to RON 66.6 bln in 2020, according to a report compiled by KeysFin, quoted by Economica.net.

The experts estimate that the industry will be driven this year by a combination of inflationary pressures and the positive impact on the production segment made by relaxation measures.

The market has increased by 2.6% year-on-year and doubled in value terms compared to 2010, KeysFin’s report also says.

The figures look impressive - but the nominal GDP has also doubled over the same period resulting in a steady ratio of the pharma industry (as defined by KeysFin) to GDP, namely 6.3%.

While its size hasn’t thus increased so much, the profitability of the pharma industry rose faster, according to the figures compiled by KeysFin.

In 2020, the aggregated net result of the pharma companies (net profit minus net loss) increased by almost 19% compared to the previous year and by over 346% compared to the level of 2010, to RON 3.2 bln.

The figures indicate major improvement in the average net profit margin to 4.8% in 2020 from 4.1% in 2019 and some 2.2% in 2010. 

(Photo: Serhii Bobyk/ Dreamstime)

iulian@romania-insider.com

Normal
Profile picture for user iuliane
Iulian Ernst
Senior Editor

Iulian studied physics at the University of Bucharest, and he sees himself as a physicist in the broadest sense of the word. He also studied economics at Charles University in Prague and Central European University in Budapest, after a master’s program in business administration at Bucharest Academy of Economic Studies. Since recently, he’s been exploring coding and data analysis for business and economics. As a freelancer, he worked for nearly two decades as an analyst for ISI Emerging Markets, Euromonitor International, Business New Europe, but also as a consultant for OMV Petrom and UkrAgroConsult. Iulian was part of the founding team of Ziarul Financiar. At Romania Insider, which he joined in 2018, he is reviewing the latest economic developments for the premium bulletins and newsletters. He would gladly discuss topics such as macroeconomics, emerging markets, Prague, energy sector including renewable, Led Zeppelin, financial services, as well as tech start-ups and innovative technologies. Email him at iulian@romania-insider.com. 

 

Study: Pharma sales to grow by 5% this year driven by inflation, relaxation

The aggregated but not consolidated sales of producers, distribution firms and retailers in the pharmaceutical industry will rise by some 5% to RON 70 bln (EUR 14 bln) after the 2.6% advance to RON 66.6 bln in 2020, according to a report compiled by KeysFin, quoted by Economica.net.

The experts estimate that the industry will be driven this year by a combination of inflationary pressures and the positive impact on the production segment made by relaxation measures.

The market has increased by 2.6% year-on-year and doubled in value terms compared to 2010, KeysFin’s report also says.

The figures look impressive - but the nominal GDP has also doubled over the same period resulting in a steady ratio of the pharma industry (as defined by KeysFin) to GDP, namely 6.3%.

While its size hasn’t thus increased so much, the profitability of the pharma industry rose faster, according to the figures compiled by KeysFin.

In 2020, the aggregated net result of the pharma companies (net profit minus net loss) increased by almost 19% compared to the previous year and by over 346% compared to the level of 2010, to RON 3.2 bln.

The figures indicate major improvement in the average net profit margin to 4.8% in 2020 from 4.1% in 2019 and some 2.2% in 2010. 

(Photo: Serhii Bobyk/ Dreamstime)

iulian@romania-insider.com

Normal
 

facebooktwitterlinkedin

1

Romania Insider Free Newsletters